Literature DB >> 16039200

Absent long-term benefit of patch versus linear reconstruction in left ventricular aneurysm surgery.

Ruediger Lange1, Thomas Guenther, Norbert Augustin, Christian Noebauer, Michael Wottke, Raymonde Busch, Norbert Mayr, Hans Meisner, Klaus Holper.   

Abstract

BACKGROUND: Endoventricular patch reconstruction of the left ventricle is considered the gold standard in surgery for left ventricular aneurysms, because of improved preservation of ventricular geometry. However, the superiority over conventional linear closure has not been demonstrated, as assessed by the long-term outcome.
METHODS: Two hundred patients (66%) underwent linear closure (group L) and 105 patients (34%) had endoventricular patch reconstruction (group D) using the Dor technique. Linear closure has been performed since 1974 and from 1985 on the Dor technique has been applied as an alternative procedure. Both patient groups differed regarding age, sex distribution, site of infarction, and indication for surgery. Prior to the operation, 71% of the patients were in New York Heart Association (NYHA) class III or IV and mean ejection fraction was 34% +/- 12%. Follow-up extends up to 25 years, with a cumulative total of 2,605 patient years.
RESULTS: Early mortality was 6.5% in group L vs 5.7% in group D (not significant [NS]). Actuarial survival after 10 years was 56 +/- 3.2%, with no difference between groups. Freedom from reoperation after 10 years was 95.6% in group L vs 95.2% in group D (NS). Preoperative risk factors for late mortality were age, left ventricular enddiastolic volume index and concomitant mitral valve surgery. The type of procedure and the date of operation had no influence on mortality. To date, 63% of the survivors are in NYHA class I and II.
CONCLUSIONS: In regard to long-term survival, rate of reoperation, and postoperative NYHA functional class, no benefit could be demonstrated when linear closure was compared with ventricular patch reconstruction for LV aneurysm repair. Hence, the technique of ventricular reconstruction may not be as important as previously thought, and at least for small aneurysms the simple and time sparing technique of linear closure may still be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039200     DOI: 10.1016/j.athoracsur.2005.03.017

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Diagnosis and management of a massive true inferobasal ventricular aneurysm ante perforationem.

Authors:  F Eberhardt; T Hanke; J Weil; U K H Wiegand; J Gellissen
Journal:  Clin Res Cardiol       Date:  2006-09-28       Impact factor: 5.460

2.  Left ventricular aneurysmal repair within 30 days after acute myocardial infarction: early and mid-term outcomes.

Authors:  Bektas Battaloglu; Nevzat Erdil; Vedat Nisanoglu
Journal:  Tex Heart Inst J       Date:  2007

3.  Posterobasal left ventricular aneurysms: surgical treatment and long-term outcomes.

Authors:  Mehmet Erdem Toker; Oruc Alper Onk; Saleh Alsalehi; Hasan Sunar; Rahmi Zeybek; Mehmet Balkanay; Cevat Yakut
Journal:  Tex Heart Inst J       Date:  2013

4.  A new shape for an old function: lasting effect of a physiologic surgical restoration of the left ventricle.

Authors:  Marco Cirillo; Andrea Amaducci; Emmanuel Villa; Margherita Dalla Tomba; Federico Brunelli; Zen Mhagna; Giovanni Troise; Eugenio Quaini
Journal:  J Cardiothorac Surg       Date:  2006-11-03       Impact factor: 1.637

5.  Impact of surgical ventricular restoration on early and long-term outcomes of patients with left ventricular aneurysm: A single-center experience.

Authors:  Jun Yan; Shu-Lin Jiang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

6.  Unrecognized concomitant ventricular septal rupture and left ventricular aneurysm 10 months after myocardial infarction in a patient presenting with chronic heart failure.

Authors:  Masashi Kawamura; Osamu Monta; Kana Shibata; Yasushi Tsutsumi
Journal:  BMC Cardiovasc Disord       Date:  2021-11-17       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.